The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of VISTA expression in patients with malignant pleural mesothelioma treated with nivolumab: Results of a retrospective multi-institutional analysis (HOT1901).
 
Hiroshi Yokouchi
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroshi Nishihara
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Incyte Japan; MSD; Novartis; Pfizer
Consulting or Advisory Role - NLAC; Secom Medical System
Research Funding - Chugai Pharma; Mitsubishi Space Software Inc; Sanofi/Aventis
 
Yoshiyuki Kenmotsu
Honoraria - AstraZeneca Japan; Boehringer Ingelheim Seiyaku; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyorin; Lilly Japan; Takeda
Travel, Accommodations, Expenses - Chugai Pharma; Eisai; MSD
 
Kosuke Tsuji
No Relationships to Disclose
 
Takayuki Kishikawa
No Relationships to Disclose
 
Hajime Kikuchi
No Relationships to Disclose
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo KK; Merck; Ono Pharmaceutical
 
Yutaro Nagano
No Relationships to Disclose
 
Kenya Kanazawa
No Relationships to Disclose
 
Jun Sugisaka
Honoraria - AstraZeneca; Kyowa Kirin International
 
Yoshinori Minami
Speakers' Bureau - AstraZeneca; Chugai Pharma; GlaxoSmithKline; Merck; Novartis; Ono Pharmaceutical; Sanofi
 
Yutaka Yamada
No Relationships to Disclose
 
Ryo Morita
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Taiho Pharmaceutical
 
Aya Suzuki
No Relationships to Disclose
 
Ayumu Takahashi
No Relationships to Disclose
 
Yasutaka Kawai
No Relationships to Disclose
 
Noriaki Sukoh
No Relationships to Disclose
 
Keiki Yokoo
Honoraria - AstraZeneca Japan; Boehringer Ingelheim Seiyaku; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; MSD; Nippon Kayaku; Takeda
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD
 
Toshiyuki Harada
No Relationships to Disclose
 
Satoshi Oizumi
Honoraria - AstraZeneca; Bristol-Myers Squibb K.K.; Chugai Pharma; Eisai; Merck; MSD K.K.; Nihonkayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)